Read by QxMD icon Read


Colten Wendel, Helena Zakrzewski, Bruce Carleton, Mahyar Etminan, Frederick S Mikelberg
PURPOSE: To determine the association of post-operative topical prostaglandin analog (PGA) or topical beta-blocker use and the incidence of pseudophakic cystoid macular edema (CME). METHODS AND PATIENTS: This was a nested case control study. All adult patients who underwent cataract surgery between January 1, 2006 and December 31, 2016 and who were enrolled in the PharMetrics Plus database were eligible for inclusion. The association between post-operative topical PGAs (bimatoprost, latanoprost and travoprost/travoprost-z) or beta-blocker (betaxolol, levobunolol and timolol) use and the incidence of pseudophakic CME was assessed by conditional logistic regression...
March 2, 2018: Journal of Glaucoma
Jonathan S Myers, Imran Masood, Dana M Hornbeak, Jose I Belda, Gerd Auffarth, Anselm Jünemann, Jane Ellen Giamporcaro, Jose M Martinez-de-la-Casa, Iqbal Ike K Ahmed, Lilit Voskanyan, L Jay Katz
INTRODUCTION: This study evaluates long-term outcomes of two trabecular micro-bypass stents, one suprachoroidal stent, and postoperative prostaglandin in eyes with refractory open angle glaucoma (OAG). METHODS: Prospective ongoing 5-year study of 80 eligible subjects (70 with 4-year follow-up) with OAG and IOP ≥ 18 mmHg after prior trabeculectomy and while taking 1-3 glaucoma medications. Subjects received two iStent® trabecular micro-bypass stents, one iStent Supra® suprachoroidal stent, and postoperative travoprost...
February 23, 2018: Advances in Therapy
Luca Agnifili, Rodolfo Mastropasqua, Vincenzo Fasanella, Lorenza Brescia, Barbara Scatena, Francesco Oddone, Leonardo Mastropasqua
PURPOSE: To investigate, using in vivo confocal microscopy (IVCM), the Meibomian gland (MG) features and conjunctival goblet cell density (GCD) in glaucomatous patients controlled with prostaglandin/timolol fixed combinations (PTFCs). METHODS: In this cross-sectional study, sixty Caucasian patients treated with PTFCs, fifteen with latanoprost+timolol (L+T) unfixed combination, and fifteen controls were enrolled. Patients underwent the Ocular Surface Disease Index (OSDI) questionnaire, tear film break-up time (BUT), corneal staining, Schirmer test I (STI), and IVCM of MGs and goblet cells (GCs)...
February 2, 2018: Journal of Glaucoma
Ferdinand Rodríguez-Agramonte, Juan Carlos Jiménez, José Raúl Montes
OBJECTIVE: To describe the prevalent side effects of prostaglandin analogues (PA) in a Hispanic population and their effect on quality of life (QOL). PATIENTS AND METHODS: This is a cross-sectional study conducted in a tertiary medical facility in which patients were evaluated in a single visit. Total of 14 participants in the study, 10 women and 4 men. Ages ranged from 26-78 years old. Subjects underwent a single full Oculoplastic evaluation by two physicians; one was blinded on patient medical history and assessed for PA side effects...
December 2017: Puerto Rico Health Sciences Journal
El Roy Dixon, Theresa Landry, Subha Venkataraman, Nancy Gustafson, Craig Salem, Yasmin Bradfield, Leyla Ali Aljasim, Robert Feldman
PURPOSE: To evaluate efficacy and safety of travoprost in pediatric patients with ocular hypertension or glaucoma and demonstrate its noninferiority to timolol. METHODS: Patients aged 2 months to <18 years with glaucoma or ocular hypertension were randomized to receive travoprost (0.004%) or timolol eye drops (0.25% for patients aged 2 months to <3 years and 0.5% for patients ≥3 years old) for 3 months in this double-masked, parallel-group study. Intraocular pressure (IOP) was measured and patients were evaluated at 2 weeks, 6 weeks, and 3 months after treatment...
September 6, 2017: Journal of AAPOS: the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus
Shinichiro Ohtani, Kimiya Shimizu, Ryohei Nejima, Fumie Kagaya, Makoto Aihara, Takuya Iwasaki, Nobuyuki Shoji, Kazunori Miyata
Purpose: To investigate the effects of the long-term use of prostaglandin analogs for glaucoma treatment on the indigenous flora of the conjunctiva. Methods: Bacterial isolates were collected from the conjunctival sacs of 68 patients at Miyata Eye Hospital from February to September 2014, who had been receiving continuous monotherapy with prostaglandin analogs for glaucoma for at least 1 year. Minimum inhibitory concentrations of levofloxacin, gatifloxacin, moxifloxacin, cefmenoxime, tobramycin, chloramphenicol, and erythromycin against the isolates were measured to determine susceptibility...
August 1, 2017: Investigative Ophthalmology & Visual Science
Takako Miki, Tomoko Naito, Miyuki Fujiwara, Ryoichi Araki, Rieko Kiyoi, Yusuke Shiode, Atsushi Fujiwara, Yuki Morizane, Fumio Shiraga
For primary open angle glaucoma (POAG), laser treatment or surgery is used when the target intraocular pressure (IOP) cannot be achieved by pharmacological agents, such as prostaglandin (PG) analogs; these drugs also have varied effects. We retrospectively reviewed the medical records of 74 POAG patients (74 eyes) whose IOP was inadequately controlled by PG analogs (bimatoprost [13 eyes], latanoprost [34 eyes], tafluprost [11 eyes], and travoprost [16 eyes]) and underwent primary trabeculectomy. The proportion of patients with no recurrent IOP elevation within 24 months post-trabeculectomy was significantly (P < 0...
2017: PloS One
Hee Weon Kim, Youn Joo Choi, Kyung Wha Lee, Min Joung Lee
BACKGROUND: Prostaglandin analogs (PGAs) are commonly used to treat glaucoma because of their powerful intraocular pressure lowering effect. However, various periorbital changes associated with the use of PGAs have been reported. We investigated the incidence of periorbital changes in Korean patients who were treated with PGAs, and analyzed clinical factors associated with superior sulcus deepening. METHODS: This study included 58 glaucoma patients who were treated with latanoprost, travoprost, or bimatoprost unilaterally...
July 17, 2017: BMC Ophthalmology
Thomas A Berk, Jella A An, Iqbal Ike K Ahmed
PURPOSE: To report the first case of inadvertent cyclodialysis cleft and hypotony requiring surgical repair following ab-interno trabeculotomy (AIT) using the Trabectome device, and the postoperative clinical results following direct suture cyclopexy. METHODS: A 55-year-old man with hypotonous maculopathy secondary to cyclodialysis cleft inadvertently created 3 years earlier during AIT using the Trabectome device was referred for repair. Direct suture cyclopexy was performed and topical homatropine and dexamethasone drops were prescribed postoperatively...
August 2017: Journal of Glaucoma
Kamran Rahmatnejad, Christopher J Rapuano, Parul Ichhpujani, Sheryl S Wizov, Marlene R Moster, Lisa A Hark, L Jay Katz
PURPOSE: To assess ocular surface changes in participants using latanoprost with benzalkonium chloride (Xalatan) and travoprost with SofZia (Travatan Z). METHODS: In this prospective, open-label, nonrandomized cohort study, participants were classified into two groups: group 1 (n=28) naive to glaucoma therapy, group 2 (n=27) on previous Xalatan monotherapy in both eyes. Both groups started (or continued) Xalatan in the right eye and Travatan Z in the left eye. Baseline, 1-, and 2-month measurements of tear breakup time (TBUT), corneal staining score, conjunctival staining score, conjunctival hyperemia score, tear production, and intraocular pressure were obtained...
June 14, 2017: Eye & Contact Lens
Suzan Guven Yilmaz, Cumali Degirmenci, Yunus Emre Karakoyun, Emil Yusifov, Halil Ates
PURPOSE: To evaluate the effect of bimatoprost/timolol maleate fixed combination (BTFC), latanoprost/timolol maleate fixed combination (LTFC), and travoprost/timolol maleate fixed combination (TTFC) on 24-h intraocular pressure (IOP) in patients with open-angle glaucoma. METHODS: This prospective, observer-masked, randomized study included 50 patients with primary open-angle glaucoma. All patients were using hypotensive lipids and timolol maleate fixed combination treatment for ≥4 weeks and had an IOP ≤ 21 mmHg...
June 14, 2017: International Ophthalmology
Katsuhiro Ohyama, Haruna Kawakami, Michiko Inoue
Topical prostaglandin F2α (PGF2α) analogs are widely used as the first line of therapy for glaucoma. Systemic PGF2α is suggested to increase blood pressure. Some ophthalmic formulations with β-receptor blocking or α-receptor stimulating actions are reported to cause systemic adverse events such as a decrease in heart rate and blood pressure. The objective of this study was to evaluate the association between topical PGF2α analogs and blood pressure elevation. We analyzed the reports obtained from the Food and Drug Administration Adverse Event Reporting System (FAERS) database from the first quarter of 2004 until the end of 2015 and the Japanese Adverse Drug Event Report (JADER) database from April 2004 to January 2016 for signal detection using reporting odds ratio (ROR), a method of disproportionality analyses...
2017: Biological & Pharmaceutical Bulletin
Erin Stahl, Dominique Bremond-Gignac, Theresa Landry, Mike Curtis, Kinfemichael Gedif, Sami Al Shahwan, El Roy Dixon
PURPOSE: To evaluate the systemic pharmacokinetics (PKs) of travoprost 0.004% preserved with Polyquad(®) (TRAVATAN(®)) in pediatric patients with glaucoma or ocular hypertension. METHODS: This was a phase 1, open-label, multicenter clinical study of patients aged ≥2 months to <18 years. Patients received daily administration of travoprost 0.004% preserved with Polyquad in both eyes for 7 days. Plasma samples were collected 30 min before the final dose and at 10, 20, 40, and 80 min postdose...
June 2017: Journal of Ocular Pharmacology and Therapeutics
John Berdahl, Lilit Voskanyan, Jonathan S Myers, Dana M Hornbeak, Jane Ellen Giamporcaro, L Jay Katz, Thomas W Samuelson
IMPORTANCE: Additional data are sought regarding treatment options for glaucoma, a major cause of global blindness. BACKGROUND: The study assessed outcomes following standalone implantation of two second-generation trabecular micro-bypass stents and postoperative topical prostaglandin in eyes with open-angle glaucoma not controlled on two preoperative medications. DESIGN: The study design is a prospective, nonrandomized, open-label study at a tertiary-care ophthalmology centre...
April 6, 2017: Clinical & Experimental Ophthalmology
Chanikarn Patradul, Visanee Tantisevi, Anita Manassakorn
PURPOSE: To determine factors related to prostaglandin-associated periorbitopathy (PAP) and its prevalence in glaucoma or ocular hypertension (OHT) patients using prostaglandins analogs (PGAs). DESIGN: A cross-sectional study. METHODS: A study of glaucoma or OHT patients, using topical PGAs for at least 3 months, was performed. Eyes treated with PGAs were photoraphed and independently evaluated for PAP by 2 glaucoma specialists using at least 4 out of 7 clinical appearances...
May 2017: Asia-Pacific Journal of Ophthalmology
David F Chang, Eric D Donnenfeld, L Jay Katz, Lilit Voskanyan, Iqbal Ike K Ahmed, Thomas W Samuelson, Jane Ellen Giamporcaro, Dana M Hornbeak, Kerry D Solomon
PURPOSE: To evaluate the long-term intraocular pressure (IOP)-lowering effect and safety parameters following treatment with two trabecular micro-bypass stents and topical prostaglandin in phakic eyes with open-angle glaucoma (OAG) not controlled on two preoperative medications. METHODS: This prospective, single-arm, unmasked study enrolled 39 qualified phakic eyes with OAG not controlled on 2 medications, preoperative medicated IOP of 18-30 mmHg, and IOP following medication washout of 22-38 mmHg...
2017: Clinical Ophthalmology
Simon Fabian Lerner, Ki Ho Park, Douglas A Hubatsch, Valeriy Erichev, Jose A Paczka, Timothy V Roberts
Objective. To evaluate the efficacy and tolerability of travoprost 0.004%/timolol 0.5% fixed-dose combination (TTFC) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) inadequately controlled on beta-blocker monotherapy. Methods. In this phase IV, open-label study, 156 patients on beta-blocker monotherapy with mean intraocular pressure (IOP) between 18 and 32 mmHg were randomized (no washout period) to receive TTFC for 8 weeks (TTFC group) or to continue beta-blocker monotherapy for 4 weeks followed by TTFC for the remaining 4 weeks (beta-blocker group)...
2017: Journal of Ophthalmology
Weerawat Kiddee, Supreeya Atthavuttisilp
BACKGROUND: To compare the effect of selective laser trabeculoplasty (SLT) and travoprost on 24-hour IOP fluctuations in primary open-angle glaucoma (POAG) and normal-tension glaucoma (NTG). METHODS: Sixty eyes were included. Sixteen and 14 eyes of POAG patients were randomized to receive 360° SLT or 0.004% travoprost, respectively. Fourteen and 16 eyes of NTG patients were randomized to receive either SLT or travoprost, respectively. The 24-hour IOP data were collected before treatment and 6 to 8 weeks after treatment...
February 2017: Medicine (Baltimore)
Małgorzata Krupa, Michał Chodyński, Anna Ostaszewska, Piotr Cmoch, Iwona Dams
Tafluprost (AFP-168, 5) is a unique 15-deoxy-15,15-difluoro-16-phenoxy prostaglandin F2α (PGF2α) analog used as an efficacious ocular hypotensive agent in the treatment of glaucoma and ocular hypertension, as monotherapy, or as adjunctive therapy to β-blockers. A novel convergent synthesis of 5 was developed employing Julia-Lythgoe olefination of the structurally advanced prostaglandin phenylsulfone 16, also successfully applied for manufacturing of pharmaceutical grade latanoprost (2), travoprost (3) and bimatoprost (4), with an aldehyde ω-chain synthon 17...
January 31, 2017: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
Tadashi Nakano, Shiro Mizoue, Nobuo Fuse, Aiko Iwase, Shun Matsumoto, Keiji Yoshikawa
BACKGROUND: We have shown a decrease in mean intraocular pressure (IOP) by switching to travoprost/timolol fixed combination (TTFC) in subjects receiving prostaglandin analogue (PGA) monotherapy and requiring additional medication in a previous report. For analyzing factors affecting IOP reduction, baseline IOP and preceding PGA were selected as statistically and clinically significant factors. In this report, we examine IOP-lowering effect and adverse drug reactions by preceding PGA...
2017: Clinical Ophthalmology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"